中国普外基础与临床杂志

中国普外基础与临床杂志

异鼠李素对胃癌细胞增殖及凋亡的影响

查看全文

目的 观察异鼠李素对人胃癌细胞 MKN28 增殖及凋亡的影响,并探索其中可能的机制。 方法 将不同浓度(0、5、10、20、40、80 mmol/L)的异鼠李素作用于 MKN28 细胞,24 h 后收集细胞利用 CCK8 法检测 MKN28 细胞的活性,BrdU/PI 双掺入法测定细胞 DNA 合成及细胞周期,Annexin Ⅴ/PI 流式细胞术检测细胞凋亡,继而通过免疫印迹法检测 MKN28 细胞中凋亡及增殖相关蛋白的变化。 结果 随着异鼠李素浓度的增高,MKN28 细胞活性逐渐下降,IC50 为 62 μmol/L,同时细胞周期进程减慢,表现为处于 S 期的细胞比例减少(P<0.05),凋亡实验证实细胞凋亡明显增加。而免疫印迹法实验提示随着异鼠李素浓度的增加,Bax、p53 及 p21 抑癌基因明显增加,而 Bcl-2 及 Mcl-1 促癌基因表达明显下降。 结论 从本研究结果提示,异鼠李素可能通过 p53 等凋亡相关蛋白抑制人胃癌细胞胞 MKN28 的增殖及周期进程,并且促进其细胞凋亡。

关键词: 异鼠李素; 胃癌; 增殖; 凋亡

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. Coburn N, Cosby R, Klein L, et al. Staging and surgical approaches in gastric cancer: A systematic review. Cancer Treat Rev, 2017, 63: 104-115.
2. Charalampakis N, Economopoulou P, Kotsantis I, et al. Medical management of gastric cancer: a 2017 update. Cancer Med, 2017 Dec 13. doi: 10.1002/cam4.1274. [Epub ahead of print].
3. Cheng X, Lu Y. A review of capecitabine-based adjuvant therapy for gastric cancer in the Chinese population. Future Oncol, 2017 Dec 18. doi: 10.2217/fon-2017-0558. [Epub ahead of print].
4. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol, 2006, 12(3): 354-362.
5. 李延武, 张有成. 胃癌淋巴结转移及其组织病理特征的回顾性研究. 中国普外基础与临床杂志, 2017, 24(5): 572-579.
6. 朱信强, 张明, 丁闯, 等. 不同病理类型进展期胃癌的预后因素分析. 中国普外基础与临床杂志, 2017, 24(5): 580-586.
7. Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol, 2006, 24(18): 2903-2909.
8. Kim JE, Lee DE, Lee KW, et al. Isorhamnetin suppresses skin cancer through direct inhibition of MEK1 and PI3-K. Cancer Prev Res (Phila), 2011, 4(4): 582-591.
9. Li Q, Ren FQ, Yang CL, et al. Anti-proliferation effects of isorhamnetin on lung cancer cells in vitro and in vivo. Asian Pac J Cancer Prev, 2015, 16(7): 3035-3042.
10. Samson P, Lockhart AC. Biologic therapy in esophageal and gastric malignancies: current therapies and future directions. J Gastrointest Oncol, 2017, 8(3): 418-429.
11. Yang JH, Kim SC, Kim KM, et al. Isorhamnetin attenuates liver fibrosis by inhibiting TGF-β/Smad signaling and relieving oxidative stress. Eur J Pharmacol, 2016, 783: 92-102.
12. Li Y, Chi G, Shen B, et al. Isorhamnetin ameliorates LPS-induced inflammatory response through downregulation of NF-κB signaling. Inflammation, 2016, 39(4): 1291-1301.
13. Wang J, Gong HM, Zou HH, et al. Isorhamnetin prevents H2O2-induced oxidative stress in human retinal pigment epithelial cells. Mol Med Rep, 2018, 17(1): 648-652.
14. Hu S, Huang L, Meng L, et al. Isorhamnetin inhibits cell proliferation and induces apoptosis in breast cancer via Akt and mitogen-activated protein kinase kinase signaling pathways. Mol Med Rep, 2015, 12(5): 6745-6751.
15. Ruan Y, Hu K, Chen H. Autophagy inhibition enhances isorhamnetin-induced mitochondria-dependent apoptosis in non-small cell lung cancer cells. Mol Med Rep, 2015, 12(4): 5796-5806.
16. Li C, Yang D, Zhao Y, et al. Inhibitory effects of isorhamnetin on the invasion of human breast carcinoma cells by downregulating the expression and activity of matrix metalloproteinase-2/9. Nutr Cancer, 2015, 67(7): 1191-1200.